Notice2023-24550
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 7, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 214 (Tuesday, November 7, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 214 (Tuesday, November 7, 2023)]
[Notices]
[Pages 76837-76838]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-24550]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
<a href="/cdn-cgi/l/email-protection#b2c2d7c6d7c09cc6c7dcd5f2dcdbda9cd5ddc4"><span class="__cf_email__" data-cfemail="7505100110075b01001b12351b1c1d5b121a03">[email protected]</span></a>. Licensing information and copies of the patent
applications listed below may be obtained by communicating with the
Technology Transfer and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases, 5601 Fishers Lane,
Rockville, MD, 20852; tel. 301-496-2644. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
patent applications related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows.
Beta Globin Mimetic Peptides and Their Use
Description of Technology: Feedback vasodilation by endothelium-
derived nitric oxide (NO) is under the regulation of globins. Inventors
discovered that not only the alpha globin but also the beta globin
subunits of hemoglobin are expressed in the human artery wall, with
beta globin interacting directly with endothelium-derived nitric oxide
synthase (eNOS). This discovery of tetrameric hemoglobin binding to
eNOS has led inventors to develop novel mimetic peptides that disrupt
the binding of beta globin to eNOS, diminishing the ability of
hemoglobin to restrict NO release and thereby enhancing NO-mediated
feedback vasodilation. These agents can be used to increase NO
signaling from endothelial cells and thus inhibit, prevent, or reverse
vasoconstriction.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Novel peptides to treat vascular diseases characterized by
vasoconstriction, excess alpha adrenergic signaling, or insufficient
nitric oxide signaling. Applications could range from cerebral
vasospasm to pulmonary hypertension, to chronic kidney disease, to
transfusion medicine, to erectile dysfunction, and to exercise
physiology.
Competitive Advantages:
<bullet> New pathway for regulation of vasoconstriction/
vasodilation that is separate from the pathways that current products
available for treating nitric oxide deficiency target. Combination
therapy with current vasoconstriction/vasodilation medications of
different mechanisms may be possible.
<bullet> Enhancement of NO release at the junction between the
endothelial cell and smooth muscle cell may provide greater potency and
fewer off-target effects than other forms of NO delivery.
Development Stage:
<bullet> Peptides have been tested in human and canine arteries ex
vivo.
[[Page 76838]]
Inventors: Drs. Hans Ackerman (NIAID), Steven Brooks (NIAID),
Phillip Cruz (NIAID), Rolf Swenson (NHLBI).
Publications: Brooks, SD et al. ``Hemoglobin Interacts with
Endothelial Nitric Oxide Synthase to Regulate Vasodilation in Human
Resistance Arteries'' <a href="https://doi.org/10.1101/2021.04.06.21255004">https://doi.org/10.1101/2021.04.06.21255004</a> (This
article is a preprint and has not been certified by peer review).
Intellectual Property: HHS Reference No. E-060-2022-0-US-01; U.S.
Provisional Application No. 63/328,615, filed on April 7, 2022; HHS
Reference No. E-060-2022-0-PCT-02; PCT Application No. PCT/US2023/
065432, filed on April 6, 2023.
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or <a href="/cdn-cgi/l/email-protection#e09085948592ce94958e87a08e8988ce878f96"><span class="__cf_email__" data-cfemail="1464716071663a60617a73547a7d7c3a737b62">[email protected]</span></a>, and reference E-060-2022.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize the invention. For collaboration
opportunities, please contact Peter Tung at 240-669-5483, or
<a href="/cdn-cgi/l/email-protection#d1a1b4a5b4a3ffa5a4bfb691bfb8b9ffb6bea7"><span class="__cf_email__" data-cfemail="463623322334683233282106282f2e68212930">[email protected]</span></a>.
Dated: November 1, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-24550 Filed 11-6-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 7, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.